Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic.

Reuniting 180+ Preclinical, Translational, Discovery, Pharmacology, and Biology experts to share case studies in improving target selection, facilitating biomarker discovery, and achieving clinical translatability, the 9th Tumor Models San Francisco Summit is the definitive industry forum uniting the West Coast ecosystem of pharma and biotech to collaboratively advance the frontier of oncology research to the clinic.

Event link here.